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Abstract
Introduction:	Brain-	derived	neurotrophic	factor	(BDNF)	has	an	important	role	in	the	
neurogenesis and neuroplasticity of the brain. This systematic review was designed 
to	 examine	 the	 association	between	BDNF	Val66Met	 (rs6265)	 polymorphism	and	
four	cognitive	domains—attention	and	concentration,	executive	function,	verbal	flu-
ency,	and	memory,	respectively.
Methodology: Primary literature search was performed using search engines such as 
PubMed	and	Scopus.	Observational	studies	that	evaluated	the	neurocognitive	per-
formances	in	relation	to	BDNF	polymorphism	within	human	subjects	were	included	
in	 this	 review,	 while	 animal	 studies,	 overlapping	 studies,	 and	 meta-	analysis	 were	
excluded.
Results:	 Forty	 of	 82	 reviewed	 studies	 (48.8%)	 reported	 an	 association	 between	
Val66Met	polymorphism	and	neurocognitive	domains.	The	proportion	of	the	studies	
showing	positive	findings	in	cognitive	performances	between	Val/Val	homozygotes	
and	Met	 carriers	was	 comparable,	 at	 30.5%	 and	18.3%,	 respectively.	 The	 highest	
percentage	of	positive	association	between	Val66Met	polymorphism	and	neurocog-
nition	was	reported	under	the	memory	domain,	with	26	of	63	studies	(41.3%),	fol-
lowed	by	18	of	47	studies	(38.3%)	under	the	executive	function	domain	and	four	of	
23	 studies	 (17.4%)	 under	 the	 attention	 and	 concentration	domain.	 There	were	no	
studies	showing	an	association	between	Val66Met	polymorphism	and	verbal	fluency.	
In	particular,	Val/Val	homozygotes	performed	better	in	tasks	related	to	the	memory	
domain,	while	Met	carriers	performed	better	in	terms	of	executive	function,	in	both	
healthy individuals and clinical populations.
Conclusion:	While	numerous	studies	report	an	association	between	Val66Met	poly-
morphism	and	neurocognitive	changes	in	executive	function	and	memory	domains,	
the	effect	of	Met	allele	has	not	been	clearly	established.
K E Y W O R D S
attention,	brain-derived	neurotrophic	factor,	executive	control,	memory,	neuroprotection
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1  | INTRODUC TION
The	brain-	derived	neurotrophic	factor	(BDNF)	belongs	to	the	neu-
rotrophin superfamily and has an essential role in the neurogenesis 
and	neuroplasticity	of	the	brain	(Matsuo	et	al.,	2009).	The	signaling	
BDNF	 supports	 the	 survival	 of	 existing	 neurons	 and	 encourages	
the proliferation and differentiation of new neurons and synapses 
in	both	the	central	and	peripheral	nervous	system	 (Acheson	et	al.,	
1995;	Huang	&	Reichardt,	 2001).	 In	 the	brain,	BDNF	 is	 highly	 ex-
pressed	 in	 the	 hippocampus,	 cortex,	 and	 basal	 forebrain	 and	 has	
an important role in regions that are vital to learning and memory 
(Bekinschtein,	Cammarota,	&	Katche,	2008).
The	expression	of	BDNF	is	encoded	by	the	BDNF	gene	which	has	
numerous	 polymorphisms.	 BDNF	 gene	 encodes	 for	 the	 precursor	
polypeptide	(pre-	pro-	BDNF)	which	is	proteolytically	cleaved	to	gen-
erate	pro-	BDNF	and	mature	BDNF.	Pro-	BDNF	is	known	to	modulate	
neuronal	structure	and	long-	term	hippocampal-	plasticity	(Bath	&	Lee,	
2006;	Binder	&	Scharfman,	2004).	The	most	extensively	studied	sin-
gle	nucleotide	polymorphism	(SNP)	in	the	BDNF	gene	is	the	G196A	
polymorphism	 (rs6265).	 The	 G196A	 polymorphism	 occurs	 in	 the	
proregion	of	BDNF,	resulting	in	an	amino	acid	substitution	of	valine	
for	methionine	at	codon	position	66	(Val66Met).	This	polymorphism	
change	has	been	linked	to	aberrant	sorting	of	pro-	BDNF	into	secre-
tory	vesicles	and	decreased	activity-	dependent	 secretion	of	BDNF	
which	constitutes	the	main	process	in	the	regulation	of	extracellular	
levels	of	BDNF	(Wei	et	al.,	2012).	There	has	also	been	suggestion	by	a	
study that this polymorphism may influence the interaction between 
mature	and	pro-	BDNF,	affecting	the	stability	of	the	complex	formed	
between	the	two	and	attenuating	the	ability	of	BDNF	to	inhibit	hip-
pocampal	long-	term	depression	(Uegaki	et	al.,	2017).
In	view	of	the	importance	of	BDNF	in	the	central	nervous	system	
(CNS)	and	the	functional	consequences	of	its	SNP,	numerous	genetic	
studies	have	evaluated	the	association	between	the	BDNF	rs6265	
polymorphism with cognitive performance in various disease states. 
Recent studies have also focused their interest in implications of 
BDNF	on	the	pathogenesis	of	brain-	related	disorders	such	as	neuro-
degenerative	and	psychiatric	diseases	(Adachi,	Numakawa,	Richards,	
Nakajima,	&	Kunugi,	2014;	Yang,	Ren,	Zhang,	Chen,	&	Hashimoto,	
2017).	As	BDNF	is	highly	expressed	in	regions	of	the	CNS	that	mod-
ulate	 learning	 and	memory,	 it	would	 be	 of	 interest	 to	 understand	
how	 the	 BDNF	 rs6265	 polymorphism	 influence	 specific	 cognitive	
domains	 such	 as	 the	 attention	 and	 concentration,	 executive	 func-
tion,	verbal	fluency,	and	memory.
Therefore,	this	systematic	review	was	conducted	to	evaluate	the	
relevant	studies	regarding	associations	between	the	SNP	Val66Met	
and neurocognitive domains.
2  | METHODS
2.1 | Literature search strategy
A	systematic	primary	literature	search	was	conducted	using	PubMed	
and	 Scopus	 in	 July	 2015.	 The	 search	 included	 articles	 published	
exclusively	 in	English	dated	up	to	1	May	2017.	No	screening	limits	
were imposed in terms of the publication dates. The literature search 
was	performed	using	Medical	Subject	Headings	and	from	combina-
tions	of	relevant	keywords,	such	as	“BDNF,”	“brain-	derived	neuro-
trophic	factor,”	“Val66Met,”	“polymorphism,”	and	“neurocognition”.	
Bibliographies of relevant articles were also reviewed.
2.2 | Inclusion/exclusion criteria
Published studies were included into the systematic review if they 
fulfilled	the	following	inclusion	criteria:	(a)	evaluated	cognitive	per-
formance	 in	 relation	 to	 the	BDNF	 rs6265	 polymorphism	 in	 either	
a	 healthy	 population	 or	 a	 specific	 clinical	 population,	 (b)	 reported	
the	allele	and	genotype	distribution	in	the	study	population,	and	(c)	
utilized	traditional	neuropsychological	batteries	to	assess	cognitive	
function.
In	vitro	research,	animal	research,	editorials,	systematic	reviews,	
and	meta-	analysis	were	excluded.	Studies	were	also	excluded	if	the	
Mini	Mental	State	Examination	(MMSE)	and	Intelligence	Quotient	
(IQ)	 have	 been	 used	 to	 evaluate	 cognitive	 performance	 in	 the	
human	 population.	 This	 is	 because	 MMSE	 not	 only	 lacks	 sensi-
tivity	 in	 identifying	mild	cognitive	 impairment,	but	 the	scores	are	
also	 influenced	 by	 demographic	 factors	 such	 as	 age,	 education,	
cultural,	 and	 socioeconomic	background.	Conversely,	 studies	uti-
lizing	IQ	test	as	an	outcome	were	excluded	because	IQ	test	is	not	
a comprehensive method for evaluating the various cognitive do-
mains.	Studies	that	utilized	functional	magnetic	resonance	imaging	
(fMRI)	as	the	sole	outcome	to	measure	brain	functioning	were	also	
excluded.
2.3 | Data extraction
Three	 investigators	 independently	extracted	 the	data	using	a	pre-
designed,	piloted	form.	Each	study	was	reviewed,	and	the	relevant	
information	 was	 extracted	 and	 compiled.	 The	 following	 informa-
tion	was	extracted	from	each	study:	study	objectives,	study	design,	
study	 population	 characteristics	 (disease	 states,	 age,	 gender,	 and	
education	level),	total	number	of	study	participants,	genotype	distri-
bution,	and	the	type	of	outcome	measures.
The	review	was	carried	out	to	evaluate	the	effect	of	Val66Met	
polymorphism	on	four	cognitive	domains:	(a)	attention	and	concen-
tration,	(b)	executive	function,	(c)	verbal	fluency,	and	(d)	memory.
The attention and concentration domain determine the content 
of	consciousness	and	influence	the	quality	of	conscious	experience,	
while	 the	executive	 function	domain	 represents	 the	ability	 to	 rea-
son,	 plan,	 and	execute.	Verbal	 fluency	domain	 is	 related	 to	 verbal	
functioning,	 which	 involves	 the	 semantic	 and	 phonemic	 fluency.	
Memory	 encompasses	 a	 broad	 domain	which	 includes	 declarative	
memory	tasks	for	verbal	tasks,	associative	memory	as	well	as	work-
ing memory that can be used for arithmetical processing.
Due	to	the	huge	heterogeneity	 in	terms	of	study	design,	study	
population,	and	the	outcome	measurements	among	the	various	re-
viewed	studies,	meta-	analysis	was	not	performed	in	this	review.
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3  | RESULTS
A	 total	 of	 1,665	 articles	 were	 identified.	 Irrelevant	 studies	 were	
excluded	through	abstracts	review	and	evaluation	of	the	nature	of	
the	studies.	A	total	of	82	unique	articles	fulfilled	the	predetermined	
inclusion–exclusion	criteria	(Figure	1).	The	number	of	studies	evalu-
ating each cognitive domain was identified; attention and concentra-
tion	(n	=	23),	executive	function	(n	=	47),	verbal	fluency	(n	=	18),	and	
memory	(n	=	63).	The	included	studies	examined	genetic	association	
with neurocognition in healthy patients and other disease states. 
In	 total,	 40	 of	 the	 82	 reviewed	 studies	 (48.8%)	 (Aas	 et	al.,	 2013;	
Alfimova,	Korovaitseva,	Lezheiko,	&	Golimbet,	2012;	Altmann	et	al.,	
2016;	Avgan	et	al.,	 2017;	Barbey	et	al.,	 2014;	Canivet	 et	al.,	 2015;	
Cao	et	al.,	2016;	De	Beaumont,	Fiocco,	Quesnel,	Lupien,	&	Poirier,	
2013;	 Egan,	 Kojima,	 &	 Callicott,	 2003;	 Freundlieb	 et	al.,	 2015;	
Gajewski,	Hengstler,	Golka,	Falkenstein,	&	Beste,	2011;	Gong	et	al.,	
2009;	Gonzalez	et	al.,	2016;	Gonzalez-	Giraldo	et	al.,	2014;	Gosselin	
et	al.,	 2016;	 Ho,	 Andreasen,	 Dawson,	 &	 Wassink,	 2007;	 Huang	
et	al.,	2014;	Jasinska	et	al.,	2016;	Kim	et	al.,	2016;	Lamb,	Thompson,	
McKay,	Waldie,	 &	 Kirk,	 2015;	 Lee,	 Baek,	 &	 Kim,	 2015;	 Lim	 et	al.,	
2013,	2016;	Miyajima	et	al.,	2008;	McAllister	et	al.,	2012;	Nagata,	
Shinagawa,	 Nukariya,	 Yamada,	 &	 Nakayama,	 2012;	 Narayanan	
et	al.,	2016;	Ng	et	al.,	2016;	Raz,	Rodrigue,	Kennedy,	&	Land,	2009;	
Richter-	Schmidinger	 et	al.,	 2011;	 Rybakowski,	 Borkoswka,	Czerski,	
Skibinska,	&	Hauser,	2003;	Rybakowski	et	al.,	2006;	Schofield	et	al.,	
2009;	 Szabo	 et	al.,	 2013;	 Tan	 et	al.,	 2005;	 Tukel	 et	al.,	 2012;	 van	
der	Kolk	et	al.,	2015;	Yin,	Hou,	Wang,	Sui,	&	Yuan,	2015;	Yogeetha	
et	al.,	2013;	Zhang	et	al.,	2012)	reported	a	significant	association	be-
tween	Val66Met	polymorphism	and	the	neurocognitive	domains	of	
interest.
3.1 | Attention/concentration domain
A	 total	 of	 23	 studies	 evaluated	 the	 association	 between	 the	
BDNF	 polymorphism	 and	 the	 attention/concentration	 domain	
(Alfimova	 et	al.,	 2012;	 Cherubin	 et	al.,	 2014;	 da	 Rocha,	 Malloy-	
Diniz,	Lage,	&	Correa,	2011;	Dennis	et	al.,	2011;	Freundlieb	et	al.,	
2012;	 Freundlieb	 et	al.,	 2015;	 Gatt	 et	al.,	 2007;	Ho	 et	al.,	 2006;	
Huang	 et	al.,	 2014;	 Kim	 et	al.,	 2016;	 Lim	 et	al.,	 2013;	 Lin	 et	al.,	
2016;	Mezquida	et	al.,	2016;	Narayanan	et	al.,	2016;	Oroszi	et	al.,	
2006;	Schofield	et	al.,	2009;	Swardfager	et	al.,	2011;	Szabo	et	al.,	
2013;	Thow,	Summers,	Summers,	Saunders,	&	Vickers,	2017;	Tukel	
et	al.,	2012;	Ward	et	al.,	2015;	Yu	et	al.,	2008;	Zhang	et	al.,	2012).	
Ten	of	these	studies	focused	on	healthy	subjects	(Alfimova	et	al.,	
2012;	Cherubin	et	al.,	2014;	Dennis	et	al.,	2011;	Freundlieb	et	al.,	
2012,	2015;	Gatt	et	al.,	2007;	Huang	et	al.,	2014;	Lim	et	al.,	2013;	
Schofield	et	al.,	2009;	Ward	et	al.,	2015),	 and	 the	 rest	evaluated	
samples	 of	 different	 disease	 states	 such	 as	 Alzheimer’s	 disease	
(n	=	1)	(Lin	et	al.,	2016),	cardiovascular	diseases	(n	=	2)	(Swardfager	
et	al.,	 2011;	 Szabo	 et	al.,	 2013),	 obsessive-	compulsive	 disorder	
(n	=	2)	 (da	 Rocha	 et	al.,	 2011;	 Tukel	 et	al.,	 2012),	 schizophrenia	
(n	=	5)	 (Ho	 et	al.,	 2006;	 Kim	 et	al.,	 2016;	Mezquida	 et	al.,	 2016;	
Zhang	et	al.,	2012,	2016),	traumatic	brain	injury	(n	=	2)	(Narayanan	
et	al.,	 2016;	 Yu	 et	al.,	 2008),	 and	 systemic	 lupus	 erythematous	
(n	=	1)	(Oroszi	et	al.,	2006).
Among	 the	 reviewed	 studies,	 four	 studies	 (17.4%)	 (Kim	 et	al.,	
2016;	Narayanan	et	al.,	2016;	Szabo	et	al.,	2013;	Zhang	et	al.,	2012)	
observed	significant	positive	association	between	BDNF	Val66Met	
polymorphism and the attention/concentration domain. In a study 
conducted	in	patients	with	mild	traumatic	brain	 injury,	Val/Val	ho-
mozygotes	were	reported	to	perform	better	in	domains	of	attention/
F IGURE  1 Flow	chart	of	the	inclusion	
and	exclusion	process	of	the	study
Search strategy: “BDNF” AND “Val66Met” AND “polymorphism” or 
“BDNF” AND “Val66Met” AND “neurocognition”
2 databases searched: 
PubMed (n = 889), Scopus (n= 776)
Abstracts reviewed for 
relevance to Val66Met 
polymorphism on 
neurocognition
N = 1359 excluded
N = 306
Number of articles screened for Eligibility: PubMed (n = 210), Scopus (n = 96)
Manual review of reference lists of identified studies = 0 nonredundant studies identified
N = 82
Studies after initially excluding studies
N = 224 excluded
n = 8 animal studies
n = 20 reviews
n = 195 article overlapping
n= 1 case-control study
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concentration	over	 time	 (Narayanan	et	al.,	 2016).	Conversely,	Met	
carriers	were	reported	to	perform	better	than	Val/Val	homozygotes	
in attention/concentration domain in another study focusing on el-
derly	 population	with	 cardiovascular	 diseases	 (Szabo	 et	al.,	 2013).	
In	studies	conducted	in	the	schizophrenic	population,	one	reported	
that	 Val/Val	 homozygotes	 had	 better	 attention	 performance	 than	
carriers	of	Met/Met	homozygotes	(Zhang	et	al.,	2012),	while	another	
study	reported	the	association	of	Val	allele	with	poorer	neurocog-
nitive	 function	 in	 the	 attention/concentration	 domain	 (Kim	 et	al.,	
2016).
3.2 | Executive function domain
Forty-	seven	 relevant	 studies	were	 identified	within	 the	 executive	
function domain. Twenty studies evaluated on healthy subjects 
(Alfimova	et	al.,	2012;	Cherubin	et	al.,	2014;	Dennis	et	al.,	2011;	De	
Beaumont	et	al.,	2013;	Erickson	et	al.,	2013;	Freundlieb	et	al.,	2012;	
Freundlieb	 et	al.,	 2015;	 Gong	 et	al.,	 2009;	 Gajewski	 et	al.,	 2011;	
Ghisletta	 et	al.,	 2014;	 Gonzalez	 et	al.,	 2016;	 Harris	 et	al.,	 2006;	
Huang	et	al.,	2014;	Lim	et	al.,	2013;	Schofield	et	al.,	2009;	Thibeau,	
McFall,	Wiebe,	Anstey,	&	Dixon,	2016;	Thow	et	al.,	2017;	Ward	et	al.,	
2014,	 2015;	Wilkosc	 et	al.,	 2016),	 and	 the	 rest	 evaluated	 samples	
of	different	disease	 states	 such	as	Alzheimer’s	disease	 (n	=	4)	 (Lee	
et	al.,	2015;	Lin	et	al.,	2016;	Nagata	et	al.,	2011,	2012),	Parkinson’s	
disease	 (n	=	3)	 (Altmann	et	al.,	 2016;	Bialecka	et	al.,	 2014;	 van	der	
Kolk	et	al.,	2015),	cardiovascular	diseases	(n	=	2)	 (Swardfager	et	al.,	
2011;	Szabo	et	al.,	2013),	obsessive-	compulsive	disorder	(n	=	2)	(da	
Rocha	et	al.,	2011;	Tukel	et	al.,	2012),	schizophrenia	and	bipolar	dis-
order	(n	=	7)	(Egan	et	al.,	2003;	Ho	et	al.,	2006;	Kim	et	al.,	2016;	Lee	
et	al.,	2016;	Mezquida	et	al.,	2016;	Rybakowski	et	al.,	2003,	2006),	
traumatic	brain	 injury	 (n	=	4)	 (Barbey	et	al.,	2014;	McAllister	et	al.,	
2012;	Narayanan	et	al.,	2016;	Yu	et	al.,	2008),	depression	(n	=	1)	(Yin	
et	al.,	2015),	multiple	sclerosis	(n	=	1)	(Fera	et	al.,	2013),	breast	can-
cer	patients	 (n	=	1)	 (Ng	et	al.,	2016),	systemic	 lupus	erythematosus	
(n	=	1)	(Oroszi	et	al.,	2006),	and	psychosis	(n	=	1)	(Aas	et	al.,	2013).
Out	of	the	47	studies,	18	studies	(38.3%)	(Alfimova	et	al.,	2012;	
Altmann	 et	al.,	 2016;	 Barbey	 et	al.,	 2014;	 Freundlieb	 et	al.,	 2015;	
Gonzalez	 et	al.,	 2016;	Kim	et	al.,	 2016;	 Lim	et	al.,	 2013;	 Lee	 et	al.,	
2015;	McAllister	et	al.,	2012;	Nagata	et	al.,	2012;	Narayanan	et	al.,	
2016;	Ng	et	al.,	2016;	Rybakowski	et	al.,	2003,	2006;	Szabo	et	al.,	
2013;	Tukel	et	al.,	2012;	van	der	Kolk	et	al.,	2015;	Yin	et	al.,	2015)	
reported	 significant	 association	 between	 BDNF	 Val66Met	 poly-
morphism	and	 the	executive	 function	domain.	Among	 these	 stud-
ies,	 11	 studies	 (23.4%)	 (Alfimova	 et	al.,	 2012;	 Barbey	 et	al.,	 2014;	
Freundlieb	et	al.,	2015;	Gonzalez	et	al.,	2016;	Kim	et	al.,	2016;	van	
der	 Kolk	 et	al.,	 2015;	 McAllister	 et	al.,	 2012;	 Nagata	 et	al.,	 2012;	
Ng	 et	al.,	 2016;	 Szabo	 et	al.,	 2013;	 Yin	 et	al.,	 2015)	 reported	 that	
Met	 carriers	 performed	 significantly	 better	 than	Val/Val	 homozy-
gotes	in	healthy	controls	and	populations	with	Alzheimer’s	disease,	
Parkinson’s	 disease,	 cardiovascular	 diseases,	 traumatic	 brain	 in-
jury,	 and	depression.	One	 study	 reported	 that	 genotypes	of	Met/
Met	 homozygotes	 performed	 the	worst	 in	 executive	 functions	 as	
compared	to	Val/Met	genotypes	and	Val/Val	genotypes	(McAllister	
et	al.,	2012).	In	contrast,	seven	studies	(14.9%)	(Altmann	et	al.,	2016;	
Lee	et	al.,	2015;	Lim	et	al.,	2013;	Narayanan	et	al.,	2016;	Rybakowski	
et	al.,	2003,	2006;	Tukel	et	al.,	2012)	showed	that	genotypes	of	Val/
Val	homozygotes	have	significantly	better	executive	function	than	
Met	carriers	in	healthy	adults	and	populations	with	Parkinson’s	dis-
ease,	traumatic	brain	injury,	obsessive-	compulsive	disorder,	and	bi-
polar disorder.
3.3 | Verbal fluency domain
Eighteen	studies	were	identified	when	evaluating	BDNF	Val66Met	
polymorphism within the verbal fluency domain. These studies eval-
uated populations of different disease states such as healthy controls 
(n	=	11)	 (Alfimova	et	al.,	2012;	De	Beaumont	et	al.,	2013;	Gajewski	
et	al.,	2011;	Gong	et	al.,	2009;	Freundlieb	et	al.,	2012,	2015;	Harris	
et	al.,	 2006;	 Huang	 et	al.,	 2014;	 Karnik,	 Wang,	 Barch,	 Morris,	 &	
Csernansky,	 2010;	 Schofield	 et	al.,	 2009;	Ward	 et	al.,	 2015),	 trau-
matic	brain	injury	(n	=	1)	(Yu	et	al.,	2008),	obsessive-	compulsive	dis-
order	 (n	=	1)	 (Tukel	et	al.,	2012),	psychosis	 (n	=	2)	 (Aas	et	al.,	2013;	
Martinho	et	al.,	2012),	Parkinson’s	disease	(n	=	1)	(van	der	Kolk	et	al.,	
2015),	cardiovascular	diseases	(n	=	1)	(Szabo	et	al.,	2013),	and	breast	
cancer	 patients	 (n	=	1)	 (Ng	 et	al.,	 2016).	 In	 all	 18	 of	 the	 identified	
studies,	none	of	 the	studies	observed	an	association	between	 the	
BDNF	Val66Met	polymorphism	and	verbal	fluency	domain.
3.4 | Memory domain
Sixty-	three	 studies	 were	 identified	 under	 the	 memory	 domain.	
The	 included	studies	had	healthy	controls	 (n	=	36)	 (Alfimova	et	al.,	
2012;	Avgan	et	al.,	2017;	Beste,	Schneider,	Epplen,	&	Arning,	2011;	
Bombardier,	Beauchemin,	Gosselin,	Poirier,	&	De	Beaumont,	2016;	
Cathomas,	Vogler,	Euler-	Sigmund,	de	Quervain,	&	Papassotiropoulos,	
2010;	 Canivet	 et	al.,	 2015;	 Chen	 et	al.,	 2015,	 2016;	 Dennis	 et	al.,	
2011;	De	Beaumont	 et	al.,	 2013;	 Erickson	 et	al.,	 2013;	 Freundlieb	
et	al.,	 2015;	 Gajewski	 et	al.,	 2011;	 Gong	 et	al.,	 2009;	 Gonzalez-	
Giraldo	 et	al.,	 2014;	 Gosselin	 et	al.,	 2016;	 Huang	 et	al.,	 2014;	
Jasinska	et	al.,	2016;	Karnik	et	al.,	2010;	Kennedy	et	al.,	2015;	Lim	
et	al.,	2013;	Liu	et	al.,	2014;	Lamb	et	al.,	2015;	Miyajima	et	al.,	2008;	
Montag	 et	al.,	 2014;	 Raz	 et	al.,	 2009;	 Richter-	Schmidinger	 et	al.,	
2011;	Schofield	et	al.,	2009;	Stuart,	Summers,	Valenzuela,	&	Vickers,	
2014;	Thow	et	al.,	 2017;	Voineskos	et	al.,	 2011;	Ward	et	al.,	 2014,	
2015;	Wilkosc	et	al.,	2016;	Wegman,	Tyborowska,	Hoogman,	Arias	
Vásquez,	 &	 Janzen,	 2016;	 Yogeetha	 et	al.,	 2013),	 dementia	 (n	=	1)	
(Kim	 et	al.,	 2015),	 Alzheimer’s	 (n	=	3)	 (Gomar,	 Conejero-	Goldberg,	
Huey,	Davies,	&	Goldberg,	2016;	Lim	et	al.,	2016;	Lin	et	al.,	2016),	
Parkinson’s	 (n	=	1)	 (Bialecka	 et	al.,	 2014),	 cardiovascular	 disease	
(n	=	2)	 (Swardfager	 et	al.,	 2011;	 Szabo	 et	al.,	 2013),	 obsessive-	
compulsive	 disease	 (n	=	1)	 (Tukel	 et	al.,	 2012),	 multiple	 sclerosis	
(n	=	1)	(Fera	et	al.,	2013),	psychosis	(n	=	2)	(Aas	et	al.,	2013;	Martinho	
et	al.,	 2012),	 depression/anxiety	 disorders	 (n	=	2)	 (Molendijk	 et	al.,	
2012;	Strauss,	Barr,	&	George,	2004),	brain	injury	(n	=	2)	(McAllister	
et	al.,	2012;	Narayanan	et	al.,	2016),	amnestic	mild	cognitive	impair-
ment	 (n	=	1)	 (Yu	 et	al.,	 2008),	 schizophrenia	 and	 bipolar	 disorders	
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(n	=	9)	 (Cao	 et	al.,	 2016;	 Egan	 et	al.,	 2003;	 Ho	 et	al.,	 2006,	 2007;	
Kim	et	al.,	2016;	Mezquida	et	al.,	2016;	Rybakowski	et	al.,	2003;	Tan	
et	al.,	 2005;	 Zhang	 et	al.,	 2016),	 systematic	 lupus	 erythematosus	
(n	=	1)	(Oroszi	et	al.,	2006),	as	well	as	patients	receiving	treatment	of	
gonadotrophin-	releasing	hormone	(n	=	1)	(Wei	et	al.,	2017).	Among	
the	reviewed	studies,	26	studies	(41.3%)	(Alfimova	et	al.,	2012;	Aas	
et	al.,	2013;	Avgan	et	al.,	2017;	Canivet	et	al.,	2015;	Cao	et	al.,	2016;	
De	Beaumont	et	al.,	2013;	Egan	et	al.,	2003;	Gajewski	et	al.,	2011;	
Gong	 et	al.,	 2009;	 Gonzalez-	Giraldo	 et	al.,	 2014;	 Gosselin	 et	al.,	
2016;	Ho	et	al.,	2007;	Huang	et	al.,	2014;	Jasinska	et	al.,	2016;	Kim	
et	al.,	2016;	Lamb	et	al.,	2015;	Lim	et	al.,	2016;	Miyajima	et	al.,	2008;	
Narayanan	et	al.,	2016;	Raz	et	al.,	2009;	Richter-	Schmidinger	et	al.,	
2011;	 Schofield	 et	al.,	 2009;	 Szabo	 et	al.,	 2013;	 Tukel	 et	al.,	 2012;	
Tan	et	al.,	2005;	Yogeetha	et	al.,	2013)	observed	significant	positive	
association	 between	BDNF	Val66Met	 polymorphism	 and	memory	
domain.
Nineteen	of	these	identified	studies	(30.2%)	(Aas	et	al.,	2013;	
Canivet	et	al.,	 2015;	Cao	et	al.,	 2016;	De	Beaumont	et	al.,	 2013;	
Egan	et	al.,	2003;	Gong	et	al.,	2009;	Gosselin	et	al.,	2016;	Ho	et	al.,	
2006;	 Jasinska	 et	al.,	 2016;	 Lamb	 et	al.,	 2015;	 Lim	 et	al.,	 2016;	
Miyajima	et	al.,	2008;	Narayanan	et	al.,	2016;	Richter-	Schmidinger	
et	al.,	 2011;	 Raz	 et	al.,	 2009;	 Schofield	 et	al.,	 2009;	 Tan	 et	al.,	
2005;	 Tukel	 et	al.,	 2012;	 Yogeetha	 et	al.,	 2013)	 favored	 Val/Val	
homozygotes	under	the	memory	domain,	 in	healthy	controls	and	
populations	with	psychosis,	depression,	Alzheimer’s	disease,	brain	
injury,	obsessive-	compulsive	disorder,	and	schizophrenia,	respec-
tively.	 Conversely,	 Met	 carriers	 were	 found	 to	 perform	 better	
in	 memory	 tasks	 in	 seven	 of	 such	 studies	 (11.1%)	 that	 evaluate	
healthy controls and populations with cardiovascular diseases and 
schizophrenia	(Alfimova	et	al.,	2012;	Avgan	et	al.,	2017;	Gajewski	
et	al.,	2011;	Gonzalez-	Giraldo	et	al.,	2014;	Huang	et	al.,	2014;	Kim	
et	al.,	2016;	Szabo	et	al.,	2013).
4  | DISCUSSION
To	our	best	knowledge,	this	is	the	first	systematic	review	conducted	
to	evaluate	 the	 association	between	Val66Met	polymorphism	and	
various	cognitive	domains.	Approximately	half	of	the	reviewed	stud-
ies indicated a presence of association with cognitive domains in 
comparison with a meta- analysis which also did not manage to es-
tablish	significant	genetic	associations	between	Val66Met	polymor-
phism	with	cognitive	domains	of	general	cognitive	ability,	memory,	
executive	functioning,	and	visual	and	cognitive	fluency	(Mandelman	
&	Grigorenko,	2012).	Across	all	four	domains	that	were	studied,	pos-
itive	studies	do	not	appear	to	favor	either	the	Val/Val	homozygote	
genotype	or	Met	carriers	because	the	proportions	of	studies	show-
ing	an	association	are	comparable,	with	25	studies	(30.5%)1	Val/Val	
homozygote	genotype	and	15	studies	(18.3%)1	favoring	that	of	Met	
carriers	(Table	1).	Without	an	association	being	clearly	established,	it	
remains	unclear	as	to	whether	the	Val66Met	polymorphism	would	
confer	a	neuroprotective	effect.	However,	the	higher	proportion	of	
reviewed	studies	reporting	an	association	suggests	that	BDNF	poly-
morphism has an influence on neurocognition.
Among	 the	 various	 cognitive	 domains	 evaluated,	 the	 domain	
of memory has the strongest evidence to suggest the role of the 
Val66Met	 polymorphism	 in	 neurocognition.	Overall,	 19	 of	 the	 re-
viewed	studies	reported	Val/Val	homozygotes	performing	better	in	
memory-	related	tasks	compared	to	Met	carriers	who	were	favored	
in seven of the total studies. This trend of higher proportion of stud-
ies	favoring	Val/Val	homozygotes	was	also	consistent	in	both	studies	
of	healthy	individuals	(Table	2)	and	clinical	populations	(Table	3).	The	
findings	that	Met	carriers	are	more	likely	to	be	adversely	affected	in	
terms of memory are aligned with the results from a meta- analysis 
previously	conducted	 (Kambeitz	et	al.,	2012).	 In	the	meta-	analysis,	
results	suggested	that	BDNF	Val66Met	polymorphism	accounts	for	
a significant proportion of the interindividual variation in memory 
performance,	including	on	both	the	structure	and	physiology	of	hip-
pocampus	(Kambeitz	et	al.,	2012).	However,	it	might	be	challenging	
to	have	a	generalization	regarding	the	influence	of	Val66Met	poly-
morphism as there were different forms of memory that were re-
viewed.	The	hippocampus	region	where	BDNF	is	highly	expressed	at	
is mainly responsible for consolidating short- term memory into long- 
term	memory	and	the	spatial	memory	(Bekinschtein	et	al.,	2008).	In	
fact,	the	distinct	phenotypes	of	memory	that	were	reviewed	include	
but	 are	 not	 limited	 to	 episodic	 memory,	 associative	memory,	 and	
working memory.
The	 various	 types	 of	 memory	 would	 require	 an	 independent	
measure	of	their	own	and	are	likely	to	be	influenced	by	BDNF	poly-
morphism	to	varying	extents.	In	order	to	make	reliable	and	reason-
able	 comparisons	 across	 studies,	 the	 measures	 for	 memory	 tests	
could	have	been	standardized	or	be	matched	to	a	defined	memory.	
To	illustrate	our	point,	while	one	study	reported	findings	that	Val/
Val	homozygotes	were	found	to	perform	better	 in	spatial	memory	
compared	 to	 the	other	genotypes,	 they	 scored	worse	on	measure	
of	visual	memory	(Yogeetha	et	al.,	2013).	In	another	study	looking	at	
schizophrenia	population,	genotypes	of	Val/Val	homozygotes	were	
found to have better verbal memory and logical episodic memory 
(Zhang	et	al.,	2012).	While	it	appears	that	Val66Met	polymorphism	
confers	 better	 verbal	memory,	 it	 is	 noteworthy	 that	 our	 reviewed	
studies	 did	 not	 show	 an	 association	with	 verbal	 fluency	 (Table	1).	
This indicates that there may be some specificity of association of 
Val66Met	polymorphisms	with	the	respective	cognitive	domains.
Another	objective	measure	worth	exploring	as	a	basis	of	com-
parison across studies is to conduct neuroimaging analysis such as 
fMRI	 to	 assess	 actual	 neural	 activation	 in	 brain	 activity.	 A	 meta-	
analysis	conducted	found	no	significant	association	between	BDNF	
Val66Met	polymorphism	and	hippocampal	 volumes	 in	healthy	hu-
mans,	with	 hippocampal	 volumes	 being	 of	 interest	 because	 it	 is	 a	
well- established brain region that has an important role in learning 
and	memory.	However,	the	findings	observed	that	Met	carriers	had	
slightly	 smaller	 hippocampal	 volumes	 than	 Val/Val	 homozygotes	
(Harrisberger	et	al.,	2014).	Given	the	current	advancement	 in	neu-
roimaging	techniques,	 it	might	be	worth	looking	at	the	exact	brain	
1Counted	as	proportion	of	studies	out	of	total	unique	studies	favoring
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regions that are activated when correlating with cognitive function. 
This would enhance our mechanistic understanding behind the bio-
logical mechanism.
With	regards	to	the	attention/concentration	domain,	 it	was	 in-
teresting to note that positive associations were identified only in 
cohorts with specific disease states. The findings from one study 
favors	Met	 carriers,	 suggesting	 that	Met	 allele	 favorably	 interacts	
with cognitive changes associated with the cardiovascular dis-
ease or that cardiovascular diseases may have affected circulating 
levels	of	BDNF,	given	 that	BDNF	 is	permeable	 to	 the	blood–brain	
barrier	 (Szabo	et	al.,	 2013).	Another	 study	 finds	 that	Met	 carriers,	
regardless	of	whether	they	were	healthy	controls	or	schizophrenic,	
performed	 worse	 than	 genotypes	 of	 Val/Val	 homozygotes	 in	 the	
attention/concentration	 domains	 (Zhang	 et	al.,	 2012).	 It	 is	 pos-
tulated	 that	 hippocampal	 neurons	 that	 contain	Met	 allele	 showed	
less	 depolarization-	induced	 BDNF	 secretion,	 resulting	 in	 reduced	
activity-	dependent	 BDNF	 release	 and	 poorer	 hippocampal-	
mediated	function	(Zhang	et	al.,	2012).
In	reviewing	the	studies	on	the	domain	of	executive	function	do-
main,	11	studies	favored	Met	carriers	compared	to	studies	that	favor	
Val/Val	homozygotes.	It	was	stated	that	the	accumulating	evidence	
in	 human	 lesion	 patients	 on	 Val66Met	 polymorphism	 has	 shown	
that	Met	allele	exerts	a	protective	effect	for	executive	function	 in	
a	 study	 on	 patients	who	had	 traumatic	 brain	 injury	 (Barbey	 et	al.,	
2014).	Similarly,	another	study	showed	that	Met	carriers	showed	a	
reduced	relationship	between	cognitive	reserve	and	executive	func-
tion	although	it	is	rationalized	that	the	lowered	functional	capacity	
can	be	attributed	to	the	negative	intrinsic	effect	of	BDNF	Met	poly-
morphism.	Consequentially,	 cognitive	 reserve	was	 reported	 to	 ac-
count	for	up	to	8.5%	of	the	variance	in	executive	function	in	Val/Val	
homozygotes	(Ward	et	al.,	2015).
There are suggestions that certain disease states could be pref-
erentially	 influenced	by	the	 impact	of	the	Met	allele	on	neurocog-
nition. The presence as well as the types of neurological conditions 
such	as	Alzheimer’s	disease,	Parkinson’s	disease,	traumatic	brain	in-
jury,	and	depression	in	the	studied	population	may	influence	whether	
Met	allele	exerts	a	neuroprotective	effect.	For	the	population	that	
has	schizophrenia,	most	studies	were	inclined	toward	favoring	Val/
Val	homozygotes	(Egan	et	al.,	2003;	Rybakowski	et	al.,	2003,	2006;	
Tan	et	al.,	2005;	Zhang	et	al.,	2012).
TABLE  1 Summary	of	literature	that	evaluated	the	association	between	Val66Met	polymorphism	and	the	respective	neurocognitive	
domains	for	(a)	Overall,	(b)	Healthy	individuals	and	(c)	Clinical	populations
(a)
Domains of interest
Attention and concentration 
(%) Executive function (%) Verbal fluency Memory (%)
Total studies 23 47 18 63
Presence of association 4	(17.4) 18	(38.3) 0 26	(41.3)
Extent	of	association
Favoring	Val/Val	homozygotes 2	(8.70) 7	(14.9) 0 19	(30.2)
Favoring	Met	carriers	(Val/Met	and	
Met/Met)
2	(8.70) 11	(23.4) 0 7	(11.1)
(b)
Domains of interest (n = total)
Attention and concentration 
(n = 23)
Executive function 
(n = 47) (%) Verbal fluency (n = 18)
Memory 
(n = 63) (%)
Number	of	studies 10 20 11 36
Presence of association 0 4	(8.51) 0 16	(25.4)
Extent	of	association
Favoring	Val/Val	homozygotes 0 1	(2.12) 0 11	(17.5)
Favoring	Met	carriers	(Val/Met	and	
Met/Met)
0 3	(6.40) 0 5	(7.94)
(c)
Domains of interest (n=total)
Attention and concentration 
(n = 23) (%)
Executive function 
(n = 47) (%) Verbal fluency (n = 18)
Memory 
(n = 63) (%)
Number	of	studies 13 27 7 27
Presence of association 4	(17.4) 14	(29.8) 0 10	(15.9)
Extent	of	association
Favoring	Val/Val	homozygotes 2	(8.70) 6	(12.8) 0 8	(12.7)
Favoring	Met	carriers	(Val/Met	and	
Met/Met)
2	(8.70) 8	(17.0) 0 2	(3.17)
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TABLE  2 List	of	reviewed	studies	showing	the	direction	of	association	between	Val66Met	polymorphism	and	the	respective	
neurocognitive	domains	for	healthy	individuals	(N	=	42)
BDNF genotype on cognitive domains (nondiseased states)
References Population
Composition of cases
Domain Association
Direction of 
effectVal/Val (%) Met carriers (%)
Thow	et	al.	(2017) Healthy	adults 322	(72.6) 121	(27.4) M,	EF − NA
Bombardier	et	al.	(2016) Healthy	adults 49	(65.3) 26	(34.7) M − NA
Wegman	et	al.	(2016) Healthy	adults 18	(48.6) 19	(51.4) M − NA
Wilkosc	et	al.	(2016) Healthy	adults N	=	460 M,	EF − NA
Thibeau	et	al.	(2016) Healthy	adults 380	(65.9) 197	(34.1) EF − NA
Chen	et	al.	(2016) Healthy	adults 113	(27.0) 304	(73.0) M − NA
Chen	et	al.	(2015) Healthy	adults 25	(22.8) 85	(77.2) M − NA
Ward	et	al.	(2015) Healthy	adults 286	(66.1) 147	(33.9) A,	EF,	VF,	M − NA
Cherubin	et	al.	(2014) Healthy	adults 261	(65.3) 139	(34.7) A,	EF − NA
Ward	et	al.	(2014) Healthy	adults 282	(66.8) 140	(33.2) M,	EF − NA
Ghisletta	et	al.	(2014) Healthy	adults 239	(66.0) 123	(34.0) EF − NA
Montag	et	al.	(2014) Healthy	adults 93	(67.0) 45	(33.0) M − NA
Stuart	et	al.	(2014) Healthy	adults 236	(65.6) 124	(34.4) M − NA
Kennedy	et	al.	(2015) Healthy	adults 79	(68.1) 37	(31.9) M − NA
Liu	et	al.	(2014) Healthy	adults 86	(26.1) 244	(73.9) M − NA
Erickson	et	al.	(2013) Healthy	adults 671	(65.0) 361	(35.0) M,	EF − NA
Freundlieb	et	al.	(2012) Healthy	adults 22	(57.9) 16	(42.1) A,	EF,	VF − NA
Dennis	et	al.	(2011) Healthy	adults 11	(50.0) 11	(50.0) A,	EF,	M − NA
Voineskos	et	al.	(2011) Healthy	adults 41	(59.5) 28	(40.5) M − NA
Beste	et	al.	(2011) Healthy	adults 119	(56.4) 92	(43.6) M − NA
Karnik	et	al.	(2010) Healthy	adults 87	(67.4) 42	(32.6) M,	VF − NA
Cathomas	et	al.	(2010) Healthy	adults 203	(61.0) 130	(39.0) M − NA
Gatt	et	al.	(2007) Healthy	adults 242	(64.7) 132	(35.3) A − NA
Harris	et	al.	(2006) Healthy	adults 589	(65.2) 315	(34.8) EF,	VF − NA
Huang	et	al.	(2014) Healthy	adults 20	(22.2) 70	(77.8) A,	EF,	VF,	M + Met	carriers	
(M)
Avgan	et	al.	(2017) Healthy	adults N = 181 M + Met	carriers	
(M)
Jasinska	et	al.	(2016) Children 55	(67.9) 26	(32.1) M + Val/Val	(M)
Gosselin	et	al.	(2016) Healthy	adults 79	(73.8) 28	(26.2) M + Val/Val	(M)
Canivet	et	al.	(2015) Elderly 118	(57.5) 87	(42.5) M + Val/Val	(M)
Lamb	et	al.	(2015) Healthy	adults 53	(53.0) 47	(47.0) M + Val/Val	(M)
Gonzalez	et	al.	(2016) Healthy	adults N	=	167 EF + Met	carriers	
(EF)
Freundlieb	et	al.	(2015) Healthy	adults 23	(60.5) 15	(39.5) A,	EF,	VF,	M + Met	carriers	
(EF)
Gonzalez-	Giraldo	et	al.	
(2014)
Healthy	adults 129	(77.0) 39	(23.0) M + Met	carriers	
(M)
Lim	et	al.	(2013) Healthy	adults 107	(64.8) 58	(35.2) EF,	M,	A + Val/Val	(EF)
Yogeetha	et	al.	(2013) Healthy	adults 113	(62.4) 68	(37.6) M + Val/Val	(M)
De	Beaumont	et	al.	(2013) Healthy	adults 80	(60.6) 52	(39.4) M,	EF,	VF + Val/Val	(M)
Alfimova	et	al.	(2012) Healthy	adults 257	(64.0) 144	(36.0) A,	EF,	VF,	M + Met	carriers	
(EF)	(M)
(Continues)
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In	some	instances,	poorer	neurocognition	could	be	attributed	
to	neurodegenerative	diseases	 itself	 rather	than	BDNF	polymor-
phism,	 confounding	 the	 actual	 extent	 of	 effect	 from	 the	 BDNF	
genotype. Disease states which affect cognitive function may 
mask or worsen the effect of genetic polymorphism on cognition. 
While	BDNF	polymorphism	was	not	significantly	associated	with	
serum	BDNF,	this	polymorphism	is	believed	to	influence	intracel-
lular	 sorting	 of	 BDNF,	 resulting	 in	 decreased	 synaptic	 plasticity	
(Bath	 &	 Lee,	 2006;	 Binder	 &	 Scharfman,	 2004).	 The	 biological	
function	of	pro-	BDNF	is	also	not	limited	in	being	an	inactive	pre-
cursor with some suggesting that it may have an antagonistic ef-
fect	 (Bath	&	Lee,	2006;	Binder	&	Scharfman,	2004).	The	overall	
physiological functions may be better correlated by a balance of 
both	pro	and	mature	BDNF,	so	measuring	BDNF	as	a	ratio	of	pro:	
mature	forms	might	be	a	more	accurate	reflection	of	BDNF	effect	
in relation to brain disorders. There are also variations attributed 
to	the	source	of	BDNF	as	levels	differ	from	plasma	to	serum	sam-
ples.	Our	 study	 posits	 that,	without	 the	 direct	 quantification	 of	
circulating	BDNF,	it	might	be	difficult	to	evaluate	the	association	
between	BDNF	genotype	and	cognitive	function.
In	 a	 study	 involving	 patients	 with	 Alzheimer’s	 disease,	 Met	
carriers	 were	 reported	 to	 have	 better	 executive	 function.	 It	 was	
suggested	 that	Met	 carriers	 are	 protected	 from	 the	 hippocampus	
cortical	atrophy	or	subcortical	tract	changes,	leading	to	them	having	
a	 decreased	 risk	 of	Alzheimer’s	 and	 improved	performance	 in	 do-
main	related	to	executive	function	(Nagata	et	al.,	2012).	However,	it	
remains unclear if the hippocampal atrophy is attributed to neuro-
psychiatric	disorders	or	the	extent	of	contribution	genetic	polymor-
phism has on its effect.
Conversely,	 in	 another	 study	 targeting	 at	 patients	 with	 high	
level	of	beta-	amyloid	(Aβ),	it	was	reported	that	there	is	greater	hip-
pocampal	 atrophy	 found	 in	Met	 carriers.	Met	 carriers	were	 found	
to	 show	 a	 significant	 decline	 in	 executive	 functions	 compared	 to	
genotypes	of	Val/Val	homozygotes	over	a	36-	month	period	instead	
(Lim	et	al.,	2013).	Met	carriers	were	also	found	with	worse	memory	
performance	in	an	Alzheimer’s	population,	with	deleterious	effects	
of	 Aβ	 on	memory	 found	 to	 be	 greater	 in	Met	 carriers	 (Lim	 et	al.,	
2016).	 This	 suggests	 that	 high	Aβ level might have been a neces-
sary	condition	for	cognitive	decline	 in	this	context	and	that	BDNF	
Val66Met	polymorphism	has	a	downstream	moderation	of	 the	ef-
fect	of	Aβ	in	executive	function.	The	implication	of	these	findings	is	
that	cognitive	influence	of	BDNF	polymorphism	might	not	necessar-
ily be related to its effect on brain region.
Old age could also be another factor that determines the direc-
tion	of	effect	BDNF	Val66Met	polymorphism	has	on	neurocognition	
as aging is often accompanied by decrease in hippocampus volume 
which	 is	associated	with	decline	 in	episodic	memory	 (Harrisberger	
et	al.,	 2014).	 Some	 studies	 have	 demonstrated	 that	 Met	 carriers	
are	more	protected	during	 aging	 than	Val/Val	 homozygotes	when	
it	comes	to	cognitive	function	such	as	executive	functions	that	 in-
volve	the	prefrontal	cortex.	For	some	aspects	of	memory,	Met	car-
riers	 were	 found	 to	 be	 performed	 poorly	 in	 associative	 memory,	
regardless	 of	 age.	BDNF	Val66Met	polymorphism	exerts	 an	 influ-
ence regardless of age on subjective and associative memory while 
may	 exacerbate	 age-	related	 differences	 in	 prospective	 memory	
(Kennedy	et	al.,	2015).
Children	aged	between	6	and	10	who	are	Val/Val	homozygotes	
were	found	to	outperform	Met	carriers	on	tasks	that	have	a	strong	
memory	component	and	exert	lesser	effort	in	neural	activation	com-
pared	to	Met	carriers	on	fMRI	analysis	(Jasinska	et	al.,	2016).	Yet	in	
another	study	examining	the	influence	of	BDNF	Val66Met	polymor-
phism on behavioral outcome of healthy young adults between 20 
and	30	years	old,	Met	carriers	tend	toward	better	performance.	It	is	
implied that the polymorphism can be an advantage or a disadvan-
tage	depending	on	the	tasks	examined	as	each	genotype	use	slightly	
different brain activation pattern as some performance- related 
tasks	may	be	more	dependent	on	BDNF	 (Dennis	et	al.,	2011).	 It	 is	
also	plausible	 that	BDNF	Val66Met	differences	on	neurocognition	
may be dependent on different developmental stages between ne-
onates,	children,	adolescents,	and	the	elderly.	To	address	this,	there	
BDNF genotype on cognitive domains (nondiseased states)
References Population
Composition of cases
Domain Association
Direction of 
effectVal/Val (%) Met carriers (%)
Gajewski	et	al.	(2011) Healthy	adults 79	(60.3) 52	(39.7) M,	EF,	VF + Met	carriers	
(M)
Richter- Schmidinger et al. 
(2011)
Healthy	adults 51	(37.8) 84	(62.2) M + Val/Val	(M)
Gong	et	al.	(2009) Healthy	adults 219	(30.8) 582	(69.2) M,	EF,	VF + Val/Val	(M)
Schofield	et	al.	(2009) Healthy	adults 282	(59.4) 193	(40.6) M,	A,	EF,	
VF
+ Val/Val	(M)
Raz	et	al.	(2009) Healthy	adults N = 189 M + Val/Val	(M)
Miyajima	et	al.	(2008) Healthy	adults 471	(55.3) 380	(44.7) M + Val/Val	(M)
Notes.	A,	attention	and	concentration;	BDNF,	brain-	derived	neurotrophic	factor;	EF,	executive	function;	M,	memory;	VF,	verbal	fluency.	()	denotes	
percentage	of	subjects	showing	the	specified	genotype.	(−)	shows	the	lack	of	an	association	between	BDNF	genotype	with	the	cognitive	domain,	while	
(+)	shows	the	presence	of	an	association	between	BDNF	genotype	with	the	cognitive	domain.
TABLE  2  (Continued)
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TABLE  3 List	of	reviewed	studies	showing	the	direction	of	the	association	between	Val66Met	polymorphism	and	the	respective	
neurocognitive	domains	for	clinical	populations	(N	=	40)
BDNF genotype on cognitive domains (clinical population)
References Population
Composition of cases
Domain Association
Direction of 
effectVal/Val (%) Met carriers (%)
Wei	et	al.	(2017) On	GnRH	agonist 29	(74.3) 10	(25.7) M − NA
Lee	et	al.	(2016) Bipolar disorder 80	(22.5) 275	(77.5) EF − NA
Lin	et	al.	(2016) Alzheimer 55	(29.5) 131	(70.5) M,	EF,	A − NA
Gomar	et	al.	(2016) Alzheimer 153	(69.0) 69	(31.0) M − NA
Mezquida	et	al.	(2016) Schizophrenia 124	(62.6) 74	(37.4) M,	EF,	A − NA
Kim	et	al.	(2015) Dementia 300	(65.0) 160	(35.0) M − NA
Bialecka	et	al.	(2014) Parkinson 176	(72.1) 68	(27.9) M,	EF − NA
Fera	et	al.	(2013) Sclerosis 12	(46.2) 14	(53.8) M,	EF − NA
Martinho	et	al.	(2012) Psychosis 88	(67.7) 42	(32.3) M,	VF − NA
Molendijk	et	al.	(2012) Depression 82	(65.1) 44	(34.9) M − NA
da	Rocha	et	al.	(2011) OCD 82	(67.2) 40	(32.8) A,	EF − NA
Swardfager	et	al.	(2011) Cardiovascular 55	(65.5) 29	(34.5) A,	EF,	M − NA
Nagata	et	al.	(2011) Alzheimer 45	(26.6) 124	(73.4) EF − NA
Yu	et	al.	(2008) Brain Injury 31	(31.3) 68	(68.7) M,	EF,	VF,	A − NA
Oroszi	et	al.	(2006) SLE 46	(78.0) 13	(22.0) M,	A,	EF − NA
Strauss	et	al.	(2004) Depression 43	(69.3) 19	(30.7) M − NA
Zhang	et	al.	(2016) Schizophrenia N	=	1,887 A,	M − N/A
Ho	et	al.	(2007) Schizophrenia 74	(62.2) 45	(37.8) M − N/A
Nagata	et	al.	(2012) Alzheimer 41	(28.1) 105	(71.9) EF + Met/Met	(EF)
Zhang	et	al.	(2012) Schizophrenia 175	(27.0) 474	(73.0) A + Val/Val	(A)
Ho	et	al.	(2006) Schizophrenia 182	(62.1) 111	(37.9) A,	EF,	M + Val/Val	(M)
Lim	et	al.	(2016) Alzheimer 95	(34.7) 179	(65.3) M + Val/Val	(M)
Kim	et	al.	(2016) Schizophrenia 102	(76.7) 31	(23.3) M,	EF,	A + Met	carriers	
(M,	EF,	A)
Narayanan	et	al.	(2016) pTBI 16	(33.3) 32	(66.7) M,	EF,	A + Val/Val	(M,	
EF,	A)
Cao	et	al.	(2016) Depression	(Bipolar) 60	(74.1) 21	(25.9) M + Val/Val	(M)
Altmann	et	al.	(2016) Parkinson 117	(66.8) 58	(33.2) EF + Val/Val	(EF)
Ng	et	al.	(2016) Postchemotherapy 38	(26.2) 107	(73.8) EF,	VF + Met	carriers	
(EF,	VF)
Lee	et	al.	(2015) Alzheimer 16	(15.1) 90	(84.9) EF + Val/Val	(EF)
van	der	Kolk	et	al.	
(2015)
Parkinson 230	(60.0) 154	(40.0) EF,	VF + Met	carriers	
(EF)
Yin	et	al.	(2015) Depression 8	(30.8) 18	(69.2) EF + Met	carriers	
(EF)
Szabo	et	al.	(2013) Cardiovascular 77	(70.0) 33	(30.0) M,	A,	EF,	VF + Met	carriers	
(M,	A,	EF)
Barbey	et	al.	(2014) Brain injury 97	(62.2) 59	(37.8) EF + Met	carriers	
(EF)
Aas	et	al.	(2013) Psychosis 170	(68.3) 79	(31.7) M,	EF,	VF + Val/Val	(M)
Tukel	et	al.	(2012) OCD 23	(23.0) 77	(77.0) M,	A.	EF,	
VF
+ Val/Val	(M,	
EF)
McAllister	et	al.	(2012) Brain injury N	=	75 M,	EF + Met	carriers	
(EF)
(Continues)
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could be longitudinal studies that assess for the domains of interest 
over	time,	for	comparison	in	the	future.
Given	that	the	included	studies	vary	greatly	 in	terms	of	study	
designs,	sample	sizes,	and	neuropsychological	batteries	that	were	
used	to	assess	the	subjects	of	interest,	there	are	several	limitations	
in this systematic review. The lack of consistent standards through-
out	could	explain	why	results	were	not	reproducible	across	stud-
ies.	 In	 addition,	 the	 small	 sample	 size	of	 some	 studies,	 especially	
those with stricter definitions may also lack statistical power in 
their	analysis.	Moreover,	our	study	categorized	the	genotypes	col-
lectively	as	Met	carriers	to	compare	against	Val/Val	homozygotes,	
while	some	studies	may	further	differentiate	the	Met	carriers	into	
individual	Met/Val	 and	Met/Met	 genotypes	 for	 comparison.	 The	
association reported might also be influenced by ethnicity- a vari-
able that has not been adjusted for. It has been observed that dif-
ferent	 ethnic	 groups	 showed	 differences	 in	 genotypic	 frequency	
of	 the	Val66Met	polymorphism,	with	Caucasians	appearing	more	
susceptible	 to	 effects	 of	 having	Met	 alleles.	 The	 derivative	Met	
allele	 ranges	 from	0%	 in	Africa	 to	 up	 to	60%	 in	Asia,	 and	 a	17%	
frequency	in	Caucasians	(Mandelman	&	Grigorenko,	2012),	entail-
ing that patient groups may need to be matched to make a more 
representative comparison.
Moving	 forward,	 it	 might	 be	 interesting	 to	 note	 how	 BDNF	
polymorphism might have a role in cognitive function especially 
in	 terms	 of	memory.	 If	 there	 is	 indeed	 a	 significant	 association,	
genetic testing could be conducted early on patient groups to seg-
regate	 them	 to	 according	 to	 genotypes	 of	 the	 Val/Val	 homozy-
gotes	or	Met	carriers	for	active	interventions.	If	a	correlation	can	
be found with disease states that are neurological in nature and 
which	collaborate	with	neuroimaging	findings,	it	may	lend	strength	
to the argument for preemptive scanning to be carried out at the 
affected brain regions. Our reviewed studies also suggest that the 
influence of genetics on cognition could become more apparent 
under	certain	disease	states	or	aging.	While	Met	allele	is	hypoth-
esized	 to	 negatively	 affect	 intracellular	 trafficking	 and	 activity-	
dependent	 secretion	 of	 BDNF	 and	 is	 expected	 to	 cause	 poorer	
neurocognition	performance,	there	is	also	an	interplay	of	factors	
between	gene,	environment,	and	disease	state	in	determining	the	
direction	of	effect.	For	instance,	there	has	been	a	cross-	sectional	
study which found that the association between physical activity 
and	 episodic	memory	was	mediated	 by	BDNF	polymorphism,	 as	
Val/Val	homozygotes	were	 found	to	perform	significantly	better	
than	Met	 carriers	 if	 they	were	 active	 in	 physical	 activity,	 show-
ing how that environmental factor can also be a consideration 
(Canivet	et	al.,	2015).
Overall,	 consolidated	 results	 from	 our	 reviewed	 studies	 showed	
that	BDNF	polymorphisms’	relationship	with	cognition	might	be	more	
complex	than	previously	thought.	More	future	studies	could	delve	into	
the correlation between the gene loci and cognitive domains.
5  | CONCLUSION
Across	the	four	domains	that	were	studied,	approximately	half	of	the	
identified	studies	reported	an	association	between	Val66Met	poly-
morphism	with	 neurocognitive	 domains.	 In	 particular,	 Val/Val	 ho-
mozygotes	performed	better	in	tasks	related	to	the	memory	domain.	
On	the	other	hand,	Met	carriers	appear	to	give	rise	to	improved	neu-
rocognitive	performances	in	terms	of	executive	function.	The	results	
from the studies focusing on the domain of verbal fluency and atten-
tion/concentration were less conclusive. While more studies might 
be needed in the future with a more clearly defined cohort and co-
morbidities	being	adjusted	for,	our	findings	suggest	that	Val66Met	
polymorphism	may	be	associated	with	the	cognitive	domains	of	ex-
ecutive	function	and	memory	domains	although	the	effect	of	Met	
allele	remains	to	be	clearly	established.	More	consistent	replicated	
findings	of	the	Val66Met	polymorphism	with	neurocognition	are	re-
quired	in	the	future	to	extend	its	clinical	relevance.
CONFLIC T OF INTERE S T
None	declared.
ORCID
Yi Long Toh  http://orcid.org/0000-0003-2997-555X 
BDNF genotype on cognitive domains (clinical population)
References Population
Composition of cases
Domain Association
Direction of 
effectVal/Val (%) Met carriers (%)
Rybakowski	et	al.	(2006) Schizophrenia 84	(65.1) 45	(34.9) EF + Val/Val	(EF)
Tan	et	al.	(2005) Schizophrenia 28	(26.0) 80	(74.0) M + Val/Val	(M)
Egan	et	al.	(2003) Schizophrenia 138	(68.0) 65	(32.0) M,	EF + Val/Val	(M)
Rybakowski	et	al.	(2003) Bipolar 44	(81.5) 10	(18.5) EF,	M + Val/Val	(EF)
Notes.	A,	attention	and	concentration,	BDNF,	brain-	derived	neurotrophic	factor;	EF,	executive	function;	M,	memory;	VF,	verbal	fluency.	()	denotes	
percentage	of	subjects	showing	the	specified	genotype.	(−)	shows	the	lack	of	an	association	between	BDNF	genotype	with	the	cognitive	domain,	while	
(+)	shows	the	presence	of	an	association	between	BDNF	genotype	with	the	cognitive	domain.
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